AMAmir Tayaranian Marvian

Amir Tayaranian Marvian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir Tayaranian Marvian has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct regulation of Tau Monomer and aggregate uptake and intracellular accumulation in human neurons

    by Amir T. Marvian, Tabea Strauss, Qilin Tang, Benjamin J. Tuck, Sophie Keeling, Daniel Rüdiger, Negar Mirzazadeh Dizaji, Hossein Mohammad-Beigi, Brigitte Nuscher, Pijush Chakraborty, et al.

    Background: The prion-like spreading of Tau pathology is the leading cause of disease progression in various tauopathies. A critical step in propagating pathologic Tau in the brain is the transport from the extracellular environment and accumulation inside naïve neurons. Current research indicates that human neurons internalize both the physiological extracellular Tau (eTau) monomers and the pathological eTau aggregates. However, similarities or differences in neuronal transport mechanisms between Tau species remain elusive. Method: Monomers, oligomers, and fibrils of recombinant 2N4R Tau were produced and characterized by biochemical and biophysical methods. A neuronal eTau uptake and accumulation assay was developed for human induced pluripotent stem cell-derived neurons (iPSCNs) and Lund human mesencephalic cells (LUHMES)-derived neurons. Mechanisms of uptake and cellular accumulation of eTau species were studied by using small molecule inhibitors of endocytic mechanisms and siRNAs targeting Tau uptake mediators. Results: Extracellular Tau aggregates accumulated more than monomers in human neurons, mainly due to the higher efficiency of small fibrillar and soluble oligomeric aggregates in intraneuronal accumulation. A competition assay revealed a distinction in the neuronal accumulation between physiological eTau Monomers and pathology-relevant aggregates, suggesting differential transport mechanisms. Blocking heparan sulfate proteoglycans (HSPGs) with heparin only inhibited the accumulation of eTau aggregates, whereas monomers’ uptake remained unaltered. At the molecular level, the downregulation of genes involved in HSPG synthesis exclusively blocked neuronal accumulation of eTau aggregates but not monomers, suggesting its role in the transport of pathologic Tau. Moreover, the knockdown of LRP1, as a receptor of Tau, mainly reduced the accumulation of monomeric form, confirming its involvement in Tau’s physiological transport. Conclusion: These data propose that despite the similarity in the cellular mechanism, the uptake and accumulation of eTau Monomers and aggregates in human neurons are regulated by different molecular mediators. Thus, they address the possibility of targeting the pathological spreading of Tau aggregates without disturbing the probable physiological or non-pathogenic transport of Tau Monomers.


  • Four-repeat tauopathies

    by Thomas W. Rösler, Amir Tayaranian Marvian, Matthias Brendel, Niko-Petteri Nykänen, Matthias Höllerhage, Sigrid C. Schwarz, Franziska Hopfner, Thomas Koeglsperger, Gesine Respondek, Kerstin Schweyer, et al.


  • In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies

    by Amir Tayaranian Marvian, David J. Koss, Farhang Aliakbari, Dina Morshedi, Tiago Fleming Outeiro

    Alpha‐synuclein (α‐Syn) is a central player in Parkinson's disease (PD) and in a spectrum of neurodegenerative diseases collectively known as synucleinopathies. The protein was first associated with PD just over 20 years ago, when it was found to (i) be a major component of Lewy bodies and (ii) to be also associated with familial forms of PD. The characterization of α‐Syn pathology has been achieved through postmortem studies of human brains. However, the identification of toxic mechanisms associated with α‐Syn was only achieved through the use of experimental models. In vitro models are highly accessible, enable relatively rapid studies, and have been extensively employed to address α‐Syn‐associated neurodegeneration. Given the diversity of models used and the outcomes of the studies, a cumulative and comprehensive perspective emerges as indispensable to pave the way for further investigations. Here, we subdivided in vitro models of α‐Syn pathology into three major types: (i) models simulating α‐Syn fibrillization and the formation of different aggregated structures in vitro, (ii) models based on the intracellular expression of α‐Syn, reporting on pathogenic conditions and cellular dysfunctions induced, and (iii) models using extracellular treatment with α‐Syn aggregated species, reporting on sites of interaction and their downstream consequences. In summary, we review the underlying molecular mechanisms discovered and categorize protective strategies, in order to pave the way for future studies and the identification of effective therapeutic strategies. image This article is part of the Special Issue “Synuclein”.


  • The primary neuronal cells are more resistant than PC12 cells to α-synuclein toxic aggregates

    by Mansooreh Heravi, Leila Dargahi, Soha Parsafar, Amir Tayaranian Marvian, Farhang Aliakbari, Dina Morshedi


  • The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's Disease

    by Farhang Aliakbari, Hossein Mohammad-Beigi, Nasrollah Rezaei-Ghaleh, Stefan Becker, Faezeh Dehghani Esmatabad, Hadieh Alsadat Eslampanah Seyedi, Hassan Bardania, Amir Tayaranian Marvian, Joanna F. Collingwood, Gunna Christiansen, et al.

    The protein α-synuclein (αSN) aggregates to form fibrils in neuronal cells of Parkinson's patients. Here we report on the effect of neutral (zwitterionic) nanoliposomes (NLPs), supplemented with cholesterol (NLP-Chol) and decorated with PEG (NLP-Chol-PEG), on αSN aggregation and neurotoxicity. Both NLPs retard αSN fibrillization in a concentration-independent fashion. They do so largely by increasing lag time (formation of fibrillization nuclei) rather than elongation (extension of existing nuclei). Interactions between neutral NLPs and αSN may locate to the N-terminus of the protein. This interaction can even perturb the interaction of αSN with negatively charged NLPs which induces an α-helical structure in αSN. This interaction was found to occur throughout the fibrillization process. Both NLP-Chol and NLP-Chol-PEG were shown to be biocompatible in vitro, and to reduce αSN neurotoxicity and reactive oxygen species (ROS) levels with no influence on intracellular calcium in neuronal cells, emphasizing a prospective role for NLPs in reducing αSN pathogenicity in vivo as well as utility as a vehicle for drug delivery.


  • Formulation and anti-neurotoxic activity of baicalein-incorporating neutral nanoliposome

    by Farhang Aliakbari, Ali Akbar Shabani, Hassan Bardania, Hossein Mohammad-Beigi, Amir Tayaranian Marvian, Faezeh Dehghani Esmatabad, Abbas Ali Vafaei, Seyed Abbas Shojaosadati, Ali Akbar Saboury, Gunna Christiansen, et al.


  • Open Access

    Neurotoxicity of pre-incubated alpha-synuclein with neutral nanoliposomes on PC12 and SHSY5Y cell lines

    by Farhang Aliakbari, Ali Akbar Shabani, Hassan Bardania, Hadieh Alsadat, Eslampanah Seyedi, Hossein Mohammad-Beigi, Amir Tayaranianmarvian, Abbas Ali Vafaei, Abbas Shojaosadati, Ali Akbar Saboury, et al.

    Alpha-synuclein (α-Syn) is an abundant protein in the brain with high tendency to convert into toxic aggregated forms that are involved in neurons degeneration in Parkinson's patients (PD). The conversion of α-Syn toward toxic aggregates may associate with bio-membranes and the interaction between α-Syn and bio-mimic liposomes can trigger the neurotoxicity. Some inhibitors of α-Syn aggregation are potential drugs to cure PD; however, they have low stability and solubility at physiological conditions. Using nano-carriers such as nanoliposomes may overcome such defects. Nevertheless, there are few studies on nanoliposomes effects on neuronal cells and α-Syn. Herein; we investigated the neurotoxicity and also fibrinogenesis of neutral charged nanoliposomes. Thin layer evaporation method and the Mini-Extruder set were employed to formulate the nanoliposomes from Dipalmitoylphosphatidylcholine to the size of ≤ 100 nm. Fibrillation and also cytotoxicity of α-Syn treated with different concentrations of nanoliposome were measured by different assays. Neither neurotoxicity nor fibril induction were observed when α-Syn treated with different concentrations of nanoliposome (35-3000 µM). These results well indicated that nanoliposome at the concentrations, which are needed to drug delivery, not only be able to prevent fibrillation process, but also have no considerable toxic effects on the neural cells.


  • Inhibition of lysozyme fibrillation by human serum albumin nanoparticles: Possible mechanism

    by Negar Mirzazadeh Dizaji, Hossein Mohammad-Beigi, Farhang Aliakbari, Amir Tayaranian Marvian, Seyed Abbas Shojaosadati, Dina Morshedi


  • Gallic acid loaded onto polyethylenimine-coated human serum albumin nanoparticles (PEI-HSA-GA NPs) stabilizes α-synuclein in the unfolded conformation and inhibits aggregation

    by Hossein Mohammad-Beigi, Dina Morshedi, Seyed Abbas Shojaosadati, Jannik Nedergaard Pedersen, Amir Tayaranian Marvian, Farhang Aliakbari, Gunna Christiansen, Jan Skov Pedersen, Daniel E. Otzen

    The aggregation of the 140-residue protein α-synuclein (αSN) plays a major role in the pathogenesis of different neurodegenerative disorders such as Parkinson's Disease (PD).